Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Solid Tumors, Mycosis Fungoides, Melanoma
About this trial
This is an interventional treatment trial for Solid Tumors focused on measuring CD47, SIRPa, Immunotherapy, Checkpoint inhibitor
Eligibility Criteria
Inclusion Criteria:
- Histologically or cytologically documented, injectable cancer lesion (limited to solid tumors and mycosis fungoides)
- Adequate renal function
- Adequate coagulation function
- Adequate hepatic function
- Disease that has progressed on standard therapy or for whom there is no other therapy option available
Exclusion Criteria:
- Central nervous system involvement
- Significant cardiovascular disease
- Active autoimmune disease
- Active hepatitis B or C or a history of HIV infection
- Uncontrolled infection
- History of hemolytic anemia or bleeding diathesis
Sites / Locations
- City of Hope National Medical Center
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
- Memorial Sloan Kettering Cancer Center
- Oregon Health & Science University
- University of Pittsburgh Medical Center
- Inova Schar Cancer Institute
- University of Washington - Seattle Cancer Care Alliance
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
TTI-621 Monotherapy Escalation
TTI-621 Monotherapy (Single Lesion)
TTI-621 Monotherapy (Multiple Lesions)
TTI-621 + PD-1/PD-L1 Inhibitor
TTI-621 + Pegylated Interferon-α2a
TTI-621 + T-Vec
TTI-621 + Radiation
TTI-621 Escalation phase of single or multiple doses of TTI-621 delivered by intratumoral injections (various dose cohorts).
TTI-621 Single Lesion Injection Expansion Cohort
TTI-621 Multiple Lesion Injections Expansion Cohort
Combination Therapy Expansion Cohort of TTI-621 plus PD-1/PD-L1 Inhibitor
Combination Therapy Expansion Cohort of TTI-621 plus Pegylated Interferon-α2a
Combination Therapy Expansion Cohort of TTI-621 plus T-Vec
Combination Therapy Expansion Cohort of TTI-621 plus Radiation Therapy